174 related articles for article (PubMed ID: 17085505)
1. A computational study of the protein-ligand interactions in CDK2 inhibitors: using quantum mechanics/molecular mechanics interaction energy as a predictor of the biological activity.
Alzate-Morales JH; Contreras R; Soriano A; Tuñon I; Silla E
Biophys J; 2007 Jan; 92(2):430-9. PubMed ID: 17085505
[TBL] [Abstract][Full Text] [Related]
2. Insights into the structural basis of 3,5-diaminoindazoles as CDK2 inhibitors: prediction of binding modes and potency by QM-MM interaction, MESP and MD simulation.
Tripathi SK; Singh SK
Mol Biosyst; 2014 Aug; 10(8):2189-201. PubMed ID: 24909777
[TBL] [Abstract][Full Text] [Related]
3. Structural Basis of the Interaction of Cyclin-Dependent Kinase 2 with Roscovitine and Its Analogues Having Bioisosteric Central Heterocycles.
Nekardová M; Vymětalová L; Khirsariya P; Kováčová S; Hylsová M; Jorda R; Kryštof V; Fanfrlík J; Hobza P; Paruch K
Chemphyschem; 2017 Apr; 18(7):785-795. PubMed ID: 28128514
[TBL] [Abstract][Full Text] [Related]
4. Molecular Modeling and Design Studies of Purine Derivatives as Novel CDK2 Inhibitors.
Zhang G; Ren Y
Molecules; 2018 Nov; 23(11):. PubMed ID: 30423939
[TBL] [Abstract][Full Text] [Related]
5. Molecular dynamics and QM/MM-based 3D interaction analyses of cyclin-E inhibitors.
Pasha FA; Neaz MM
J Mol Model; 2013 Feb; 19(2):879-91. PubMed ID: 23086460
[TBL] [Abstract][Full Text] [Related]
6. Explicit treatment of active-site waters enhances quantum mechanical/implicit solvent scoring: Inhibition of CDK2 by new pyrazolo[1,5-a]pyrimidines.
Hylsová M; Carbain B; Fanfrlík J; Musilová L; Haldar S; Köprülüoğlu C; Ajani H; Brahmkshatriya PS; Jorda R; Kryštof V; Hobza P; Echalier A; Paruch K; Lepšík M
Eur J Med Chem; 2017 Jan; 126():1118-1128. PubMed ID: 28039837
[TBL] [Abstract][Full Text] [Related]
7. Binding free energy estimation for protein-ligand complex based on MM-PBSA with various partial charge models.
Fu T; Jin Z; Xiu Z; Li G
Curr Pharm Des; 2013; 19(12):2293-307. PubMed ID: 23082979
[TBL] [Abstract][Full Text] [Related]
8. Molecular simulation studies on the binding selectivity of 2-anilino-4-(thiazol-5-yl)-pyrimidines in complexes with CDK2 and CDK7.
Chohan TA; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Jan; 12(1):145-61. PubMed ID: 26565382
[TBL] [Abstract][Full Text] [Related]
9. Interaction energies for the purine inhibitor roscovitine with cyclin-dependent kinase 2: correlated ab initio quantum-chemical, DFT and empirical calculations.
Dobes P; Otyepka M; Strnad M; Hobza P
Chemistry; 2006 May; 12(16):4297-304. PubMed ID: 16575928
[TBL] [Abstract][Full Text] [Related]
10. An in silico exploration of the interaction mechanism of pyrazolo[1,5-a]pyrimidine type CDK2 inhibitors.
Li Y; Gao W; Li F; Wang J; Zhang J; Yang Y; Zhang S; Yang L
Mol Biosyst; 2013 Sep; 9(9):2266-81. PubMed ID: 23864105
[TBL] [Abstract][Full Text] [Related]
11. Structure of cyclin-dependent kinase 2 (CDK2) in complex with the specific and potent inhibitor CVT-313.
Talapati SR; Nataraj V; Pothuganti M; Gore S; Ramachandra M; Antony T; More SS; Krishnamurthy NR
Acta Crystallogr F Struct Biol Commun; 2020 Aug; 76(Pt 8):350-356. PubMed ID: 32744246
[TBL] [Abstract][Full Text] [Related]
12. Novel structural features of CDK inhibition revealed by an ab initio computational method combined with dynamic simulations.
Heady L; Fernandez-Serra M; Mancera RL; Joyce S; Venkitaraman AR; Artacho E; Skylaris CK; Ciacchi LC; Payne MC
J Med Chem; 2006 Aug; 49(17):5141-53. PubMed ID: 16913703
[TBL] [Abstract][Full Text] [Related]
13. Study of a ligand complexed with Cdk2/Cdk4 by computer simulation.
Jiang Y; Zou J; Gui C
J Mol Model; 2005 Nov; 11(6):509-15. PubMed ID: 15928920
[TBL] [Abstract][Full Text] [Related]
14. Molecular modeling studies to characterize N-phenylpyrimidin-2-amine selectivity for CDK2 and CDK4 through 3D-QSAR and molecular dynamics simulations.
Chohan TA; Chen JJ; Qian HY; Pan YL; Chen JZ
Mol Biosyst; 2016 Apr; 12(4):1250-68. PubMed ID: 26883408
[TBL] [Abstract][Full Text] [Related]
15. Identification of High-Affinity Inhibitors of Cyclin-Dependent Kinase 2 Towards Anticancer Therapy.
Mohammad T; Batra S; Dahiya R; Baig MH; Rather IA; Dong JJ; Hassan I
Molecules; 2019 Dec; 24(24):. PubMed ID: 31847444
[TBL] [Abstract][Full Text] [Related]
16. Extra precision docking, free energy calculation and molecular dynamics simulation studies of CDK2 inhibitors.
Tripathi SK; Muttineni R; Singh SK
J Theor Biol; 2013 Oct; 334():87-100. PubMed ID: 23727278
[TBL] [Abstract][Full Text] [Related]
17. Identification and Characterization of an Irreversible Inhibitor of CDK2.
Anscombe E; Meschini E; Mora-Vidal R; Martin MP; Staunton D; Geitmann M; Danielson UH; Stanley WA; Wang LZ; Reuillon T; Golding BT; Cano C; Newell DR; Noble ME; Wedge SR; Endicott JA; Griffin RJ
Chem Biol; 2015 Sep; 22(9):1159-64. PubMed ID: 26320860
[TBL] [Abstract][Full Text] [Related]
18. Quantum mechanical scoring: structural and energetic insights into cyclin-dependent kinase 2 inhibition by pyrazolo[1,5-a]pyrimidines.
Brahmkshatriya PS; Dobeš P; Fanfrlik J; Rezáç J; Paruch K; Bronowska A; Lepšík M; Hobza P
Curr Comput Aided Drug Des; 2013 Mar; 9(1):118-29. PubMed ID: 23157414
[TBL] [Abstract][Full Text] [Related]
19. Exploring the mechanism of action of spirooxindoles as a class of CDK2 inhibitors: a structure-based computational approach.
Abdjan MI; Shafiq M; Nerukh D; Nur-E-Alam M; Ul-Haq Z
Phys Chem Chem Phys; 2024 Jun; 26(22):16139-16152. PubMed ID: 38787638
[TBL] [Abstract][Full Text] [Related]
20. Decoding molecular mechanism of inhibitor bindings to CDK2 using molecular dynamics simulations and binding free energy calculations.
Chen J; Pang L; Wang W; Wang L; Zhang JZH; Zhu T
J Biomol Struct Dyn; 2020 Mar; 38(4):985-996. PubMed ID: 30843759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
